Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis

Impact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

(2009) Jennifer M. Polinski et al.   ARTHRITIS AND RHEUMATISM

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden

(2009) Peter Lindgren et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

The Effects of Rheumatoid Arthritis on Labor Force Participation, Work Performance, and Healthcare Costs in Two Workplace Samples

(2009) Ronald C. Kessler et al.   JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

(2008) Allan J. Wailoo et al.   ARTHRITIS AND RHEUMATISM

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

(2008) Anthony Russell et al.   CLINICAL RHEUMATOLOGY

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

(2008) Adrian Kielhorn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Economic Evaluations in Rheumatoid Arthritis

(2008) Nick Bansback et al.   PHARMACOECONOMICS